Quantitative Marrow Imaging, Marrow Reserve, And Clinical Outcomes In Patients Undergoing Radiotherapy For Hematologic And Related Disorders

September 2, 2026 updated by: M.D. Anderson Cancer Center

To create a registry for people who are undergoing or previously underwent radiotherapy for hematologic or related disorders.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Other: data collection

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Omran Saifi, MD
Phone Number: 832-829-0337
Email: OSaifi@mdanderson.org

Study Locations

United States
- Texas
  - Houston, Texas, United States, 77030
    - Recruiting
    - UT MD Anderson Cancer Center
    - Contact:
      
      Omran Saifi, MD
      
      Phone Number: 832-829-0337
      
      Email: OSaifi@mdanderson.org
    - Sub-Investigator:
      
      Omran Saifi, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

UT MD Anderson Cancer Center

Description

Inclusion Criteria

Undergoing or previously underwent radiotherapy at The University of Texas MD Anderson Cancer Center for hematologic or related disorders.
Available clinical, imaging, laboratory, treatment, and/or outcome data relevant to study objectives.
Ability to provide informed consent for prospective participation, when applicable.

Exclusion Criteria

Participants meeting any of the following criteria will be excluded:

Inability to provide informed consent, or when applicable, the absence of a legally authorized representative able to provide consent for prospective participation.
Insufficient clinical information available to support study objectives.
Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and adverse events (AEs). Time Frame: Through study completion; an average of 1 year.	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0	Through study completion; an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

Principal Investigator: Omran Saifi, MD, UT MD Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

UT MD Anderson Cancer Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 31, 2026

Primary Completion (Estimated)

December 31, 2036

Study Completion (Estimated)

December 31, 2038

Study Registration Dates

First Submitted

July 30, 2026

First Submitted That Met QC Criteria